LataMed AI Corp. (OTC: LMED), a healthcare technology company focused on Latin America, announced that its mobile healthcare application has entered the final stage of development. The company is currently completing testing, optimization, and deployment preparations, with plans to submit the app to the Apple App Store and Google Play in the coming weeks. This move is expected to transition the company from application development to public availability, providing users with a direct mobile access point to its digital healthcare ecosystem.
The application is designed to serve as a primary interface for users to access supported healthcare services and digital tools. Management believes that mobile accessibility is crucial in Latin America, where smartphones are a primary means of accessing digital services for many individuals. By launching on both major platforms, LataMed AI aims to offer a more direct and accessible way for users to engage with its evolving healthcare infrastructure, while also establishing a scalable foundation for future expansion.
Once available, the app is expected to include features such as patient-facing tools, healthcare-provider interaction, digital communications, access to medical and wellness information, and healthcare-service coordination. These features are part of the company's broader strategy to connect patients, healthcare professionals, pharmacies, insurers, payment providers, and wellness organizations within a more integrated digital healthcare environment.
Dr. Kevin Rodan Levy, CEO of LataMed AI, stated, "Our mobile application is now moving from development toward deployment, and we believe we are approaching an important milestone for LataMed AI. Our team is completing the final stages of testing and preparation, and we currently expect the application to become available through the Apple App Store and Google Play in the coming weeks, subject to the applicable platform review processes." He added, "Mobile availability is important because it provides a direct connection between users and the digital healthcare ecosystem we are building."
The company also continues to develop its artificial intelligence-supported technologies, including CardioAI, PulmoAI, and NeuroAI, which are intended to assist healthcare professionals in evaluating cardiovascular, pulmonary, and neurological health information. The mobile infrastructure is expected to provide an additional pathway for users and professionals to interact with these components of the LataMed AI ecosystem, subject to ongoing development and regulatory requirements.
Following the initial release, LataMed AI intends to evaluate additional functionality and integrations for future versions of the app. The company plans to provide updates regarding submission, availability, and functionality as milestones are completed. For more information, visit https://latamed.ai or review the company's filings with the U.S. Securities and Exchange Commission at www.sec.gov.
